市場調査レポート

バイオシミラー・バイオベター開発パイプラインのチャート

Charting the Biosimilar and Biobetter Development Pipeline

発行 FirstWord 商品コード 250781
出版日 ページ情報 英文 213 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
バイオシミラー・バイオベター開発パイプラインのチャート Charting the Biosimilar and Biobetter Development Pipeline
出版日: 2013年07月01日 ページ情報: 英文 213 Pages
概要

当レポートでは、世界における300社以上の開発中のバイオシミラー/バイオベター医薬品について調査分析し、バイオシミラーデータファイル、バイオシミラー開発分析レポートとして提供して、概略以下の構成でお届けいたします。

エグゼクティブサマリー

イントロダクション

定義・調査手法

参照製品

  • 開発中のバイオシミラー
    • バイオシミラー:予測発売日(最早日)別(米国・EU)
    • バイオシミラー:クラス・予測発売日(最早日)別(米国)
    • バイオシミラー:クラス・予測発売日(最早日)別(EU)
    • バイオシミラー開発国と地域
    • 開発中のバイオシミラー:薬剤クラス別
    • 主要なバイオシミラー企業(ポートフォリオのバイオシミラー製品数)
    • バイオシミラー開発パイプライン:化合物クラス・治療分野別
  • 抗血栓薬(B01A)
    • 血液凝固因子(B02BD)
    • その他の抗貧血製剤(B03XA)
    • ゴナドトロピン(G03GD)
    • ソマトロピン、ソマトロピン作動薬(H01AC)
    • グリコーゲン分解、副甲状腺ホルモン、類似体(H04A-H05A)
    • 抗腫瘍性モノクローナル抗体(L01XC)
    • コロニー刺激因子(L03AA)
    • インターフェロン(L03AB)
    • インターロイキン(L03AC)
    • 免疫抑制薬(L04A)
    • 筋弛緩薬、その他の筋骨格系疾患用薬(M03AX、M09AX)
  • バイオシミラー開発パイプライン:治療分野別
    • 自己免疫疾患
    • 心血管疾患
    • 内分泌・代謝性疾患
    • 血液学
    • 感染・寄生虫疾患
  • 筋骨格系疾患
    • 神経学
    • 神経筋疾患
    • 産科/婦人科
    • 腫瘍学

バイオベター

  • バイオベター開発:化合物クラス・治療分野別
    • バイオベター開発:治療分野・開発段階別
    • 開発中のバイオベター:ATCクラス別
    • 開発中のバイオベター:治療分野別
    • 皮膚科
    • 内分泌・代謝性疾患
    • 血液学
    • 感染・寄生虫疾患
    • 筋骨格系疾患
    • 神経学
    • 神経筋疾患
  • 産科/婦人科
    • 腫瘍学
    • 眼科
    • 呼吸器疾患
  • 創傷ケア

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Abstract

If you need to understand the important biosimilar and biobetter drug developments worldwide then this report is critical.

The promise of biosimilars has been great but beyond the first wave of products progress has been slow. With a number of high-value biologics, particularly monoclonal antibodies such as Herceptin, Avastin, Remicade and Humira, losing patent expiry in the coming years the potential for biosimilars remains high. With greater clarity on regulatory approval and the demand of health payers for low cost medicines, the drive to develop a viable biosimilar market will continue to grow.

Who are the companies involved? What does their portfolio look like? What stage are they at? Which products offer the best potential in terms of competitor development? Critical questions needing robust answers. That is where Charting the Biosimilar and Biobetter Development Pipeline (2013) comes in.

Charting the Biosimilar and Biobetter Development Pipeline (2013) will help you to:

  • Understand the landscape of biosimilar/biobetter development through pipeline analysis of all known biosimilar developers worldwide
  • Drill down to discover the levels of potential biosimilar and biobetter competition by therapy area, drug class, development status, and country
  • Establish the level of biosimilar/biobetter competition to leading brands
  • Learn which biosimilar developers are potential future competitors or collaborators
  • Interrogate the development portfolio of over 300 companies and discover which are the leaders in biosimilar/biobetter development
  • Identify development hotspots and know where research is taking place

NEW FULLY UPDATED EDITION INCLUDES ANALYSIS AND DATAFILE

The massively expanded second edition of this leading drug intelligence report provides a complete, practical and highly-detailed insight into the status of 868 biosimilar/biobetter drugs in development from over 300 companies worldwide. Widely considered to be the most comprehensive analysis of its type, Charting the Biosimilar and Biobetter Development Pipeline (2013) is delivered in two modules:

1. Biosimilar Datafile - New this edition!

Enjoy the practical benefits of a Microsoft Excel file containing data on biosimilar and biobetter drugs currently marketed or known to be in clinical development worldwide. Each drug can be seen in the context of data on their biologic reference products and content can readily be filtered on key indicators such as:

  • Product Name/Development Code
  • Developer(s)
  • HQ Location
  • Reference Product
  • Therapy Area
  • EU Patent Expiry
  • US Patent Expiry
  • Originator Company
  • Product Type
  • Stage of Development (US)
  • Stage of Development (EU)
  • Brand Name (reference products)
  • Sales Value (reference products)

Using the tables provided you can effortlessly drill down into the content to identify biosimilars/biobetters in development by country, company, ATC classification, stage of development, and therapeutic area. Better still, the data can easily be exported to your own analytics or competitive intelligence system.

2. Biosimilar Development Analysis Report

This completely updated and expanded report volume utilises the Datafile content to produce more than 200 clear tables, charts, graphs and maps to provide "at a glance" insights into high-level trends and significant developments. Areas covered include:

  • Leading biosimilar companies - number of biosimilar products in portfolio
  • Geographic distribution of biosimilar/biobetter research
  • Biosimilar development pipelines by 14 compound class and therapy areas
  • Biosimilar development pipelines by therapy area
  • Biobetter developments by compound class and therapy area
  • Biobetters in development by 13 therapy areas

Who Should Read This Report?

Product managers at pharma/biotech companies with original biologics: Identify how many biosimilars versions of your products are being developed and by whom Product managers at biosimilar developers: Know how many biosimilars are being developed in different therapy areas or of different originator products so that you can identify opportunity gaps/areas with less competition Heads of licensing at pharma/biotech companies: Use the database to identify biosimilars developers that may want to license in/out their products - whilst also assessing the competitive environment for any products that they may currently license. Investment managers at venture capital firms, seed funding bodies and investment banks: Assess the investment potential of companies and their development pipelines: the risks are high but potential reward is great for those that bring product to market.

Table of Contents

Executive Summary

Introduction

Definitions and methodology.

Reference products

  • Biosimilars in development.
    • Biosimilars by earliest potential launch date - US & EU
    • Biosimilars by class and earliest potential launch date in the US (total number).
    • Biosimilars by class and earliest potential launch date in the EU (total number).
    • Biosimilar developers countries and regions
    • Biosimilars in development by drug class.
    • Leading biosimilar companies - number of biosimilar products in portfolio
    • Biosimilar development pipelines by compound class and therapy area
      • Diabetes (A10A and A10B).
      • Other Alimentary Tract and Metabolism Products (A16A).
  • Antithrombotic Agents (B01A)
    • Blood Coagulation Factors (B02BD)
    • Anti-anaemic preparations, other (B03XA)
    • Gonadotropins (G03GD)
    • Somatropin and Somatropin Agonists (H01AC)
    • Glycogenolytic and Parathyroid Hormones and Analogues (H04A-H05A)
    • Antineoplastic Monoclonal Antibodies (L01XC)
    • Colony Stimulating Factors (L03AA)
    • Interferons (L03AB).
    • Interleukins (L03AC)
    • Immunosuppressants (L04A).
    • Muscle Relaxants and Other Musculoskeltal Drugs (M03AX and M09AX)
  • Biosimilar development pipelines by therapy area
    • Autoimmune disease
    • Cardiovascular disease
    • Endocrine and metabolic disorders
    • Haematology.
    • Infectious and parasitic diseases
  • Musculoskeletal disorders.
    • Neurology
    • Neuromuscular diseaseas
    • Obstetrics/gynaecology
    • Oncology

Biobetters

  • Biobetter developments by compound class and therapy area
    • Biobetter development by therapy area and stage of development.
    • Biobetters in development by ATC class.
    • Biobetters in development by therapy area
    • Dermatology
    • Endocrine and metabolic disorders
    • Haematology.
    • Infectious and parasitic diseases
    • Musculoskeletal disorders.
    • Neurology
    • Neuromuscular diseases
  • Obstetrics/gynaecology
    • Oncology
    • Ophthalmology
    • Respiratory disease
  • Wound care

TABLES (sheets)

  • Reference Products by Patent Expiry (US and EU)
  • Reference Brands by Sales (2009-2012, US$ millions)
  • Marketed Biosimilars and Biobetters
  • Biosimilars/Biobetters in Development
  • Biosimilars/Biobetters in Development by Country
  • Biosimilars/Biobetters in Development by Company
  • Biosimilars/Biobetters by ATC Classification
  • Analysis of Biosimilars/Biobetters by Compound Class and Stage of Development
  • Analysis of Biosimilar/Biobetter Development by Reference Product and Stage
Back to Top